Tirzepatide in Brazil
ANVISA-approved Mounjaro in October 2023 (T2D), with pharmacy availability since May 2025. Premium private hospital chains (Albert Einstein, Sírio-Libanês) anchor the trustworthy route; ANVISA mandates retained-prescription for all GLP-1s and actively enforces against compounded grey-market sales.
ANVISA-registered as Mounjaro since October 2023 (T2D). Pharmacy availability since May 2025. Off-label weight prescribing legal under Brazilian medical practice rules. ANVISA mandates retained-prescription for all GLP-1s — pharmacy will not dispense without it. Compounded GLP-1 grey market is large and ANVISA-contested.
What it actually costs.
Midpoint ranges, Eli Lilly brand unless noted. Updated April 2026.
Per month including endo consult + bloodwork. Premium-tier pricing reflective of Brazilian private hospital norms.
Per month at typical 5-10 mg dose. Drogasil, Drogaria São Paulo, Pague Menos retail. Hospital prescription required.
Per month including consult. Smaller private hospital chains; supply more variable than the big-two.
How to get it — on the right side of the line.
Hospital Israelita Albert Einstein
Brazil's flagship — JCI-accredited since 1999 (first ex-US), Newsweek World's Best #16 globally / #1 Brazil 2026 (seventh consecutive year). Centro de Prevenção e Tratamento da Obesidade is a named multi-disciplinary program with named obesity endocrinologists. In-house semaglutide research (SOARD 2024).
Hospital Sírio-Libanês
JCI-accredited since 2007 + JCI Primary Care 2024 (only in Brazil). Newsweek Brazil #2 (seventh consecutive year). Public Obesidade e Cirurgia Bariátrica center page lists named multi-disciplinary team.
Pharmacy retail with hospital prescription
Drogasil / Drogaria São Paulo / Pague Menos stock Mounjaro at ANVISA-channel prices. Cheapest legitimate route assuming you have an in-network hospital consult for the prescription.
What channels actually work here.
Albert Einstein, Sírio-Libanês, BP, Hospital Alemão; ANVISA channel since May 2025.
Compounded semaglutide is ANVISA-flagged grey market; Panya does not route there.
ANVISA enforces; not recommended.
Both Einstein and Sírio-Libanês run telehealth + in-person hybrid.
Brazil is premium-private-tier pricing — comparable to UAE / Singapore longevity-clinic level. Worth it for the in-network insurance flow and the JCI quality assurance, less worth it for cash-pay arbitrage seekers (Bangkok or India undercut significantly). For Brazilian-resident patients with insurance, the Einstein / Sírio route is the default.
What's actually in stock right now.
Per-brand stock state for tirzepatide in this region, sourced from cohort research and operator feedback. Each entry has a verifiedAt date so you can judge freshness. Confirm at the specific provider before booking.
ANVISA-approved Oct 2023; pharmacy availability since May 2025. Drogasil / Drogaria São Paulo / Pague Menos. Hospital prescription required (ANVISA retained-Rx mandate).
Semaglutide in Brazil
Ozempic / Wegovy / Rybelsus — GLP-1-only agonist. Novo Nordisk. Longer brand history, slightly cheaper, more reliably stocked in 2026 than tirzepatide in most markets. Rybelsus oral exists for needle-averse patients.
Match me to a vendor in Brazil.
Two minutes, five questions. Your match email has the vendor name, price, and the honest tradeoff.
We earn a small commission when you buy through recommended vendors. That is how this stays free. Vendors rank by quality signals, not paid placement.